Alnylam Pharmaceuticals (ALNY) News Today

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares edged higher today, extending recent gains as the company’s RNAi pipeline and analyst sentiment continue to draw investor attention. Here’s what moved the stock:

• Positive Sentiment: Roche and Alnylam announced they will advance zilebesiran into a Phase III trial for hypertension, underscoring strong collaboration and potential blockbuster upside for Alnylam’s late-stage pipeline. Roche and Alnylam to take zilebesiran into Phase III hypertension trial
• Positive Sentiment: Alnylam highlighted strong launch momentum for Amvuttra and reported encouraging data updates across its ATTR-CM program, reinforcing confidence in growing revenue streams from its marketed RNAi therapies. Amvuttra’s Launch And Ongoing Clinical Progress Are Positives
• Positive Sentiment: Alnylam released a new analysis from its ATTR-CM trial showing sustained benefit and safety for Amvuttra, boosting long-term commercial outlook. Alnylam reports new analysis from trial of Amvuttra for ATTR-CM
• Positive Sentiment: HC Wainwright reiterated its “buy” rating and set a $570 price target—implying over 25% upside—citing robust pipeline catalysts. HC Wainwright Reaffirms Buy Rating
• Positive Sentiment: Citigroup raised its price target on ALNY from $527 to $583 and maintained a “buy” rating, pointing to accelerating revenue from existing and upcoming RNAi products. Citigroup Raises Price Target on ALNY
• Neutral Sentiment: Alnylam management presented at Citi’s Biopharma Back to School Conference, reiterating its R&D priorities but providing no new guidance. Citi Biopharma Back To School Conference Prepared Remarks Transcript
• Neutral Sentiment: Novartis inked a $5.2 billion licensing deal with China’s Argo for heart drugs, illustrating broader M&A and licensing activity in cardiovascular—though not directly tied to Alnylam’s RNAi programs. Novartis signs up to $5.2 billion licensing deal with China's biotech Argo for heart drugs
• Neutral Sentiment: Investor letters and portfolio rundowns (e.g., ClearBridge Growth Strategy and Yahoo Finance “Should You Add ALNY”) continue to profile Alnylam but haven’t triggered material price swings. Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio?
• Neutral Sentiment: Industry headlines on the CDC’s broader public-health challenges provide context but don’t directly impact Alnylam’s financials or pipeline. InnovationRx: Inside The Crisis At The CDC
• Negative Sentiment: New startups like Corsera Health are targeting preventive heart medicines, signaling emerging competition in cardiovascular RNAi space. Startup Corsera Health aims to bring preventive heart medicine to the masses
• Negative Sentiment: Two industry veterans launched a Boston biotech with a preventive RNAi asset for cardiovascular disease, adding another potential rival to Alnylam’s pipeline. Aiming to disrupt the cardiovascular space, 2 industry vets unveil Boston biotech preventive RNAi asset